Momenta Pharmaceuticals, Inc. (MNTA) Rating Reiterated by J P Morgan Chase & Co

J P Morgan Chase & Co reissued their hold rating on shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) in a report released on Thursday. J P Morgan Chase & Co currently has a $14.00 target price on the biotechnology company’s stock.

Several other brokerages have also issued reports on MNTA. Goldman Sachs Group, Inc. (The) started coverage on shares of Momenta Pharmaceuticals in a report on Thursday, September 28th. They issued a neutral rating and a $18.00 price target on the stock. Stifel Nicolaus restated a buy rating and issued a $26.00 target price on shares of Momenta Pharmaceuticals in a research note on Thursday, August 3rd. Barclays PLC restated an equal weight rating and issued a $16.00 target price (down previously from $17.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday, October 4th. BidaskClub downgraded shares of Momenta Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, July 6th. Finally, Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a hold rating to a buy rating and set a $20.00 target price on the stock in a research note on Wednesday, October 4th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $15.00.

Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) opened at 12.95 on Thursday. Momenta Pharmaceuticals has a 12 month low of $10.75 and a 12 month high of $19.90. The company has a 50-day moving average of $16.69 and a 200 day moving average of $15.79. The company’s market capitalization is $959.03 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.50). The firm had revenue of $23.57 million for the quarter, compared to analyst estimates of $24.64 million. Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The business’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.31) EPS. Analysts forecast that Momenta Pharmaceuticals will post ($1.53) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://ledgergazette.com/2017/10/09/momenta-pharmaceuticals-inc-mnta-rating-reiterated-by-j-p-morgan-chase-co.html.

In related news, President Craig A. Wheeler sold 16,953 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $16.94, for a total transaction of $287,183.82. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, President Craig A. Wheeler sold 4,116 shares of the company’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $15.07, for a total transaction of $62,028.12. Following the transaction, the president now owns 269,231 shares in the company, valued at approximately $4,057,311.17. The disclosure for this sale can be found here. In the last quarter, insiders have sold 79,663 shares of company stock worth $1,414,498. 4.40% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. lifted its position in Momenta Pharmaceuticals by 14.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock worth $109,000 after buying an additional 834 shares in the last quarter. Tortoise Investment Management LLC acquired a new position in Momenta Pharmaceuticals during the 2nd quarter worth about $114,000. Pinebridge Investments L.P. lifted its position in Momenta Pharmaceuticals by 4.3% during the 2nd quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock worth $149,000 after buying an additional 363 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Momenta Pharmaceuticals during the 1st quarter worth about $158,0

Several other brokerages have also issued reports on MNTA. Goldman Sachs Group, Inc. (The) started coverage on shares of Momenta Pharmaceuticals in a report on Thursday, September 28th. They issued a neutral rating and a $18.00 price target on the stock. Stifel Nicolaus restated a buy rating and issued a $26.00 target price on shares of Momenta Pharmaceuticals in a research note on Thursday, August 3rd. Barclays PLC restated an equal weight rating and issued a $16.00 target price (down previously from $17.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday, October 4th. BidaskClub downgraded shares of Momenta Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, July 6th. Finally, Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a hold rating to a buy rating and set a $20.00 target price on the stock in a research note on Wednesday, October 4th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $15.00.

Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) opened at 12.95 on Thursday. Momenta Pharmaceuticals has a 12 month low of $10.75 and a 12 month high of $19.90. The company has a 50-day moving average of $16.69 and a 200 day moving average of $15.79. The company’s market capitalization is $959.03 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.50). The firm had revenue of $23.57 million for the quarter, compared to analyst estimates of $24.64 million. Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The business’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.31) EPS. Analysts forecast that Momenta Pharmaceuticals will post ($1.53) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://ledgergazette.com/2017/10/09/momenta-pharmaceuticals-inc-mnta-rating-reiterated-by-j-p-morgan-chase-co.html.

In related news, President Craig A. Wheeler sold 16,953 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $16.94, for a total transaction of $287,183.82. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, President Craig A. Wheeler sold 4,116 shares of the company’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $15.07, for a total transaction of $62,028.12. Following the transaction, the president now owns 269,231 shares in the company, valued at approximately $4,057,311.17. The disclosure for this sale can be found here. In the last quarter, insiders have sold 79,663 shares of company stock worth $1,414,498. 4.40% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. lifted its position in Momenta Pharmaceuticals by 14.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock worth $109,000 after buying an additional 834 shares in the last quarter. Tortoise Investment Management LLC acquired a new position in Momenta Pharmaceuticals during the 2nd quarter worth about $114,000. Pinebridge Investments L.P. lifted its position in Momenta Pharmaceuticals by 4.3% during the 2nd quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock worth $149,000 after buying an additional 363 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Momenta Pharmaceuticals during the 1st quarter worth about $158,000. Finally, BNP Paribas Arbitrage SA lifted its position in Momenta Pharmaceuticals by 13.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 13,393 shares of the biotechnology company’s stock worth $179,000 after buying an additional 1,570 shares in the last quarter. Institutional investors and hedge funds own 93.88% of the company’s stock.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply